Circio Holding ASA (STU:TA50) Stock Based Compensation: €0.11 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TA50 Circio Holding ASA STU:TA50
27 GF Score
Price €0.81
! 3 Warning Signs
View Full Analysis

What is Circio Holding ASA Stock Based Compensation?

Circio Holding ASA STU:TA50 +8.05% 27 Stock Based Compensation is €0.11 Mil as of Dec. 2025. GuruFocus rates STU:TA50 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Circio Holding ASA's Stock Based Compensation for the six months ended in Dec. 2025 was €0.05 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.11 Mil.

Circio Holding ASA Stock Based Compensation Related Terms

Circio Holding ASA Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Circio Holding ASA's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Circio Holding ASA Stock Based Compensation Chart

Circio Holding ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.40 0.13 0.08 0.11

Circio Holding ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.09 -0.00 0.06 0.05
STU:TA50
27GF Score
Circio Holding ASA STU:TA50
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Circio Holding ASA Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.11 Mil.

What does a Stock Based Compensation of €0.11 Mil mean?
Circio Holding ASA (STU:TA50) has a Stock Based Compensation of €0.11 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Circio Holding ASA and its competitors.
Is Circio Holding ASA's Stock Based Compensation too high?
Circio Holding ASA's current Stock Based Compensation is €0.11 Mil. Overall, Circio Holding ASA has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Circio Holding ASA's Stock Based Compensation compare to VRTX and REGN?
Circio Holding ASA's Stock Based Compensation of €0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Circio Holding ASA and its competitors. Circio Holding ASA's current Stock Based Compensation is €0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Circio Holding ASA stock overvalued right now?
Circio Holding ASA (STU:TA50) has a current Stock Based Compensation of €0.11 Mil. The current Stock Based Compensation is €0.11 Mil. Circio Holding ASA's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Circio Holding ASA (STU:TA50), the current Stock Based Compensation is €0.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Circio Holding ASA Business Description

Other Exchanges CRNA:Norway0RIS:UK
Address c/o Mesh Community AS, Tordenskiolds Gate 2, Oslo, NOR, 0160
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
27GF Score

Get the complete analysis for STU:TA50

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.81
Price